An open label, phase 2 study of biweekly Velcade [bortezomib] and intermittent Caelyx [doxorubicin-liposomal] in patients with ovarian cancer failing platinum containing regimens
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 02 Jun 2011
At a glance
- Drugs Bortezomib; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 15 Jul 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 Oct 2008 Planned end date changed from 1 Sep 2008 to 1 Sep 2009 as reported by ClinicalTrials.gov.
- 15 Mar 2008 New trial record.